Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
CDNA · against 1,336 other Healthcare companies
Ranked #756 of 1,337 · scores higher than 43% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 40–49, including CDNA · Click a bar to see the companies
A mix: stronger free cash flow yield, but weaker EBITDA yield than most Healthcare peers.
| Metric | CDNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 2.4% | 1.5% | 56% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 0.3% | 4.2% | 33% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 1.8% | -1.0% | 61% | 20% | |
| Book yieldHigher is better · 1,306 reported | 9.3% | 37.9% | 14% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 756 | 17.8B CNY (≈$2.5B) | 43 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 39 |
| 756 | 3.9B CNY (≈$549M) | 43 | 61 |
| 756 | 14.0B CNY (≈$2.0B) | 43 | 40 |
| 756 | 40.3B SEK (≈$4.0B) | 43 | 79 |
| 756 | 4.6B USD | 43 | 65 |
| 756 | 1.7B USD | 43 | 35 |
| 756 | 16.9B USD | 43 | 37 |
| 756 | 363M AUD (≈$240M) | 43 | 31 |
| 756 | 15.7B USD | 43 | 33 |